

Table 1: DCA per trial

Trial	Year	Cancer Type	Phase	Patients (N)	Female (%)	Cycle of Standard of Care	Price /Cycle (€)	Cycles (N)	DCA (€)
1	2015	Breast	III	6 2	100	Letrozol Tamoxifen	92.1 2.35	65 26	6,053
2	2015	Digestive	III	4	25	Paclitaxel	345	28	9,660
3	2016	Gynecological	III	7	100	Carboplatin + Doxorubicin Liposomal	1045	35	36,575
4	2016	Breast	III	3	100	Fulvestrant	462	65	30,030
5	2016	Lung	III	6	50	Carboplatin-Pemetrexed + Pemetrexed	9.992 + 2.375	37	72,894
6	2016	Lung	III	7	0	Nivolumab	7238	203	1,469,314
7	2017	Breast	III	9 5	100	Letrozol Tamoxifen	92.1 2.35	341 161	36,294
8	2017	Breast	II	4	100	Fulvestrant	462	31	14,322
9	2017	Breast	II	4	100	Capecitabine	43	30	1,290
10	2017	Breast	III	8	100	Ribociclib + Letrozol	4772	214	1,021,208
11	2018	Digestive	III	2	0	Folfiri + Bevacizumab	2896	21	60,816
12	2018	Lung	III	1	0	Atezolizumab	4726	16	75,616
13	2018	Sarcoma	II	5	20	Trabectedin	5820	27	157,140
14	2018	Breast	II	1	100	Eribuline	1455	15	21,825
15	2018	Gynecological	III	15	100	Carboplatin + Paclitaxel	338	361	122,018
16	2018	Gynecological	III	17	100	Cisplatin + Paclitaxel	409	182	74,438
17	2018	Breast	III	5	100	Paclitaxel + Pertuzumab + Trastuzumab Letrozol	8640 4960	198	984,370
18	2019	Breast	III	9	100	Adriamycin + Cyclophosphamide + Paclitaxel Pertuzumab + Trastuzumab	11384 4632	148	466,832
19	2019	Digestive	III	5 2	14	FOLFOX FOLFIRI	416 139	96 30	44,106
20	2019	Digestive	III	5	0	FOLFOX	416	29	12,064
21	2019	Gynecological	III	5	100	Olaparib	2646	42	111,132
22	2019	Digestive	III	6	33	Gemcitabine + Nab-paclitaxel	449	25	11,225
23	2019	Breast	III	10 6	100	Letrozol Tamoxifen	92.1 2.35	101 69	9,477
24	2019	Breast	III	7	100	Adriamycin + Cyclophosphamide + Paclitaxel	224	96	21,504
25	2019	Melanoma	II	2	0	Pembrolizumab	7534	17	128,078
26	2019	Prostate	III	2	0	Enzalutamide	3358	14	47,012
27	2020	Lung	III	2	50	Carboplatin + Etoposide	71	17	1,207
28	2020	Digestive	III	1	0	Lenvatinib	2249	10	22,490
29	2020	Breast	II	1	100	Carboplatin + Gemcitabine	249	4	996
30	2020	Gynecological	III	1	100	Topotecan	300	3	900
31	2020	Breast	II	2	100	Adriamycin + Cyclophosphamide + Paclitaxel	3072	2	6,144
								Total	5,077,030